



# Role of Patatin-Like Phospholipase Domain-Containing 3 Gene for Hepatic Lipid Content and Insulin Resistance in Diabetes

Diabetes Care 2020;43:2161–2168 | <https://doi.org/10.2337/dc20-0329>

Oana P. Zaharia,<sup>1,2</sup> Klaus Strassburger,<sup>2,3</sup> Birgit Knebel,<sup>2,4</sup> Yuliya Kupriyanova,<sup>1,2</sup> Yanislava Karusheva,<sup>1,2</sup> Martin Wolkersdorfer,<sup>5</sup> Kálmán Bódis,<sup>1,2,6</sup> Daniel F. Markgraf,<sup>1,2</sup> Volker Burkart,<sup>1,2</sup> Jong-Hee Hwang,<sup>1,2</sup> Jörg Kotzka,<sup>2,4</sup> Hadi Al-Hasani,<sup>2,4</sup> Julia Szendroedj,<sup>1,2,6</sup> and Michael Roden,<sup>1,2,6</sup> for the GDS Group\*

## OBJECTIVE

The rs738409(G) single nucleotide polymorphism (SNP) in the patatin-like phospholipase domain-containing 3 (*PNPLA3*) gene associates with increased risk and progression of nonalcoholic fatty liver disease (NAFLD). As the recently described severe insulin-resistant diabetes (SIRD) cluster specifically relates to NAFLD, this study examined whether this SNP differently associates with hepatic lipid content (hepatocellular lipids [HCL]) and insulin sensitivity in recent-onset diabetes.

## RESEARCH DESIGN AND METHODS

A total of 917 participants in the German Diabetes Study (GDS) underwent genotyping, hyperinsulinemic-euglycemic clamps with stable isotopic tracer dilution, and MRS.

## RESULTS

The G allele associated positively with HCL ( $\beta = 0.36$ ,  $P < 0.01$ ), independent of age, sex, and BMI across the whole cohort, but not in the individual clusters. Those with SIRD exhibited lowest whole-body insulin sensitivity compared with those with severe insulin-deficient (SIDD), moderate obesity-related (MOD), moderate age-related (MARD), and severe autoimmune diabetes (SAID) clusters (all  $P < 0.001$ ). Interestingly, the SIRD group presented with higher prevalence of the rs738409(G) SNP compared with other clusters and the glucose-tolerant control group ( $P < 0.05$ ). HCL was higher in the SIRD group (median 13.6% [1st quartile 5.8; 3rd quartile 19.1] compared with the MOD (6.4% [2.1; 12.4],  $P < 0.05$ ), MARD (3.0% [1.0; 7.9],  $P < 0.001$ ), SAID (0.4% [0.0; 1.5],  $P < 0.001$ ), and glucose-tolerant (0.9% [0.4; 4.9],  $P < 0.001$ ) group. Although the *PNPLA3* polymorphism did not directly associate with whole-body insulin sensitivity in SIRD, the G-allele carriers had higher circulating free fatty acid concentrations and greater adipose tissue insulin resistance compared with noncarriers (both  $P < 0.001$ ).

## CONCLUSIONS

Members of the SIRD cluster are more frequently carriers of the rs738409(G) variant. The SNP-associated adipose tissue insulin resistance and excessive lipolysis may contribute to their NAFLD.

<sup>1</sup>Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany

<sup>2</sup>German Center for Diabetes Research (DZD e.V.), München-Neuherberg, Germany

<sup>3</sup>Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany

<sup>4</sup>Institute for Clinical Biochemistry and Pathobiochemistry, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany

<sup>5</sup>Landesapotheke Salzburg, Salzburg, Austria

<sup>6</sup>Division of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

Corresponding author: Michael Roden, michael.roden@ddz.de

Received 17 February 2020 and accepted 14 May 2020

Clinical trial reg. no. NCT01055093, clinicaltrials.gov

This article contains supplementary material online at <https://doi.org/10.2337/figshare.12315737>.

\*A list of the GDS Group members and their affiliations is provided in the supplementary material online.

© 2020 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <https://www.diabetesjournals.org/content/license>.

Ectopic triglyceride storage in the liver plays an important role in the development of insulin resistance and contributes to the pathogenesis of type 2 diabetes (1–3). In line, previous cross-sectional analyses showed that patients with type 2 diabetes frequently have increased hepatocellular lipids (HCL) (3), associated with higher insulin resistance. Nevertheless, recent studies indicate that diabetes comprises several subtypes (clusters) with distinct heterogeneous features (4,5), suggesting that the traditional diabetes classification calls for revision. We have shown that the severe insulin-resistant cluster (SIRD) specifically associates with an increased prevalence of nonalcoholic fatty liver disease (NAFLD) and surrogate markers of liver fibrosis (5). The molecular mechanisms underlying this association between HCL and insulin resistance may involve inadequate mitochondrial adaptation to higher lipid flux (6) and subsequent cellular accumulation of lipid metabolites such as diacylglycerols, which inhibit proximal insulin signaling (1), or ceramides, which may act via inflammatory pathways (7).

While the current paradigm infers that acquired insulin resistance of adipose tissue and/or liver primarily leads to hepatic steatosis (3), there is growing evidence that certain gene variants relate to liver fat deposition independently of insulin resistance or even cause NAFLD. Genome-wide association studies revealed an important role of the rs738409 single nucleotide polymorphism (SNP) referring to a missense variant, which alters the protein sequence (I148M) in the patatin-like phospholipase domain-containing 3 (*PNPLA3*) gene in NAFLD (8). The G allele in this SNP associates tightly with increased risk of NAFLD (9) and also favors steatohepatitis and hepatic fibrosis (10), particularly in the context of metabolic diseases (11), subsequently contributing to increased mortality (2,12). *PNPLA3* is expressed predominantly in liver and to less extent in adipose tissue and encodes a transmembrane protein composed of 481 amino acid residues. *PNPLA3* expression is controlled by changes in nutrition and energy balance (13). While this protein likely acts primarily as a triglyceride lipase (14), it may also have lipogenic properties (15). In line, the mutation causes a loss of function without excluding the possibility of additional effects of this enzyme (16). The link between

*PNPLA3* and insulin resistance remains controversial, as studies show no relationship with insulin resistance (17), suggest an association of the gene expression with hepatic insulin resistance (15), or describe insulin resistance as a consequence of liver damage due to NAFLD progression to fibrosis (18).

Against this background, this study aimed 1) at determining whether specific diabetes subtypes, particularly the SIRD cluster, exhibit differences in the prevalence of the *PNPLA3* polymorphism and 2) at revealing possible relationships of this genotype with metabolic features such as whole-body and tissue-specific insulin sensitivity. We hypothesized that the common *PNPLA3* polymorphism associates with changes in HCL independent of insulin resistance, particularly in patients with SIRD.

## RESEARCH DESIGN AND METHODS

### Participants

All volunteers were recruited from the prospective multicenter German Diabetes Study (GDS), which includes individuals with recently diagnosed diabetes and individuals who are glucose tolerant. The GDS is approved by the ethics committee of the Medical Faculty of Heinrich Heine University Düsseldorf (reference number 4508), registered at ClinicalTrials.gov (identifier number: NCT01055093), and performed according to the Declaration of Helsinki as reported previously (19). Briefly, diagnosis of diabetes was based on current criteria (20). The control group (CON) was comprised of healthy humans presenting neither with dysglycemia, excluded by a 75-g oral glucose tolerance test (20), nor with first-degree relatives with known diabetes. Exclusion criteria comprise poorly controlled diabetes ( $\text{HbA}_{1c} > 9\%$ , 75 mmol/mol), pregnancy, acute or severe chronic heart, kidney or liver diseases (clinical signs/transaminases twofold above upper limit of normal range), acute systemic inflammation (clinical signs/ $\text{hs-CRP} > 1$  mg/dL), immunosuppressive treatment, and alcohol abuse (by questionnaire). Oral glucose-lowering medication was withdrawn 3 days prior to all metabolic tests.

This cross-sectional analysis was performed for 917 Caucasian individuals, of whom 834 had diabetes and 83 were glucose tolerant (CON). Individuals with diabetes were categorized into clusters based on an algorithm including age, BMI, glycemia, homeostasis model estimates

(HOMA of insulin resistance and HOMA of  $\beta$ -cell function), and GAD antibodies (4,5). Analyses of main metabolic parameters were also performed upon categorization as to type 1 or type 2 diabetes, as defined by the American Diabetes Association (20).

### Laboratory Analyses

Blood samples were analyzed in the biomedical laboratory of the center as previously described (19). Adipose tissue insulin resistance index was calculated from fasting concentrations of insulin and free fatty acids (FFA) (21). The fatty liver index (FLI), AST-to-platelet ratio index (APRI), FIB-4 index, and NAFLD fibrosis score were computed from routine laboratory parameters (22). GAD antibodies were measured as described previously (5).

### Modified Botnia Clamp Test

Patients underwent hyperinsulinemic-euglycemic clamp tests with frequent measurements of blood glucose, C-peptide, and insulin (19). The clamp test was preceded by an intravenous glucose tolerance test (1 mL 30% glucose infusion/kg body wt) to assess  $\beta$ -cell function. A priming insulin dose was then applied for 10 min ( $10 \text{ mU} \cdot \text{kg body wt}^{-1} \cdot \text{min}^{-1}$ ) followed by constant infusion of  $1.5 \text{ mU} \cdot \text{kg body wt}^{-1} \cdot \text{min}^{-1}$  (Insuman Rapid; Sanofi, Frankfurt, Germany). Blood glucose concentration was maintained at 90 mg/dL by a variable 20% glucose infusion. Whole-body insulin sensitivity (M value) was assessed from mean steady-state glucose infusion rates and glucose space correction (19). In a representative subgroup ( $n = 218$ ), endogenous glucose production (EGP) was measured before and during the hyperinsulinemic-euglycemic clamp test using a continuous infusion of  $[6,6\text{-}^2\text{H}_2]\text{glucose}$  (19). Fasting hepatic insulin sensitivity was computed from EGP and insulin levels after overnight fasting. Insulin-mediated EGP suppression was calculated from the ratio between EGP during clamp and fasted EGP and is given as %.

### MRS

HCL was quantified using  $^1\text{H}$ -MRS on a 3-T magnetic resonance scanner (23). Both water-suppressed and nonsuppressed  $^1\text{H}$ -MRS were taken in the identical voxel within the homogeneous part of liver tissue, avoiding major vessels and gallbladder, with a volume of interest of  $25 \times 25 \times 25 \text{ mm}^3$ . All liver spectra were processed using jMRUI software. HCL

content was calculated from the methylene peak at 1.3 ppm in water-suppressed spectra, relative to the sum of the methylene and water peaks at 4.7 ppm in water nonsuppressed spectra. Abdominal subcutaneous and visceral adipose tissue volumes were quantified by T1-weighted axial fast spin echo (24).

### Genomics

Genomic DNA was extracted from whole blood, and genotyping was conducted using real-time PCR-based allelic discrimination with probe-based genotyping assay for the rs738409 SNP in the *PNPLA3* gene (Thermo Fisher Scientific, Darmstadt, Germany) (25). The genotype concordance of >99.8% was determined using TaqMan Genotyper software v.1.3 (Thermo Fisher Scientific). The genetic variant was in Hardy-Weinberg equilibrium, and resequencing of 1% of randomly chosen individuals was done for data validation and quality control, confirming genotyping results by 100%.

### Metabolomics

Targeted identification and quantification of blood metabolites were performed using gas chromatography–, liquid chromatography–, and flow injection analysis–mass spectrometry and mass spectrometric procedures with quality-control measures as previously described (25). This analysis focused specifically on lipidomics (127 metabolites). Annotations were used to differentiate between acyl-acyl bonds (aa) and acyl-alkyl bonds (ae). None of the studied metabolites were exclusively detected in one specific cluster. No data were available for the glucose-tolerant CON group.

### Statistics

Data are presented as mean  $\pm$  SD or median (1st quartile; 3rd quartile) for continuous variables and % for categorical variables. Skewed data were log transformed before analysis (M value, alanine aminotransferase, AST, hs-CRP, HCL, triglycerides). The k-means clustering via nearest centroid approach (4) allowed for assigning each patient to a predefined cluster (4,5). Associations between parameters were evaluated using linear regression analyses and were adjusted for age, sex, and BMI. As SIRD was the focus of this analysis, comparisons with other clusters were adjusted using the Dunnett test. In the analysis of metabolites, *P* values were additionally adjusted for multiple comparisons of 127 traits using Bonferroni correction. *P* values <5% were considered to indicate statistically

significant differences or correlations. Statistical analyses were performed with SAS (version 9.4; SAS Institute, Cary, NC). Figures were drawn using GraphPad Prism (version 8.1; GraphPad, San Diego, CA).

## RESULTS

### Study Cohort Characteristics

Anthropometric and clinical data of the individuals with recent-onset diabetes, stratified according to cluster analysis (5), and of the glucose-tolerant CON group are shown in Table 1, with further stratification for G-allele carriers and noncarriers in Supplementary Table 1. Patients of the severe autoimmune diabetes (SAID) cluster were younger and had lower body mass and reduced  $\beta$ -cell function. Patients with severe insulin-deficient diabetes (SIDD) had worse glycemic control (mean HbA<sub>1c</sub> 8.8%) and  $\beta$ -cell function. SIRD patients were characterized by higher body mass and waist-to-hip ratio. Patients with mild obesity-related diabetes (MOD) showed greater body mass at younger age. Patients with mild age-related diabetes (MARD) were older and showed less severe metabolic abnormalities. The CON group was middle-aged, overweight, and—by definition—normoglycemic. Distribution of drug treatment across the study population is shown in Supplementary Table 2. Median alcohol consumption was 5.6 g/day (1st quartile 1.9; 3rd quartile 15.5) (males 6.0 g/day [1.9; 19.0] and females 4.9 g/day [1.6; 15.1]).

In a subgroup (*n* = 130), body composition was assessed showing no difference in adipose tissue volumes between G-allele carriers and noncarriers (subcutaneous 21,980  $\pm$  11,500 vs. 20,517  $\pm$  9,769 cm<sup>3</sup> and visceral 2,570  $\pm$  1,763 vs. 2,913  $\pm$  2,254 cm<sup>3</sup>, respectively).

### Distribution of the rs738409 Variants in the *PNPLA3* Gene Across the Clusters

The common C/C genotype was less prevalent in the SIRD cluster compared with the other clusters (adjusted *P* < 0.05 vs. CON; *P* < 0.05 vs. SAID; *P* < 0.05 vs. MOD; *P* < 0.05 vs. MARD) (Fig. 1), except for SIDD (*P* = 0.68). Genotypes containing the minor alleles, C/G and G/G, were pooled for the subsequent analyses due to the low number of homozygous carriers.

### Insulin Sensitivity in Diabetes Clusters Depending on the rs738409 *PNPLA3* Variants

The G-allele carrier SIRD patients had higher circulating FFA levels than noncarrier SIRD

patients (*P* < 0.001) (Fig. 2A). In line, adipose tissue insulin resistance was higher in SIRD (median 17.1 [1st quartile 9.3; 3rd quartile 24.5]) than in CON (4.3 [2.4; 6.0], *P* < 0.001), MARD (6.7 [4.1; 11.6], *P* < 0.001), and SAID (5.7 [2.7; 11.2], *P* < 0.001) but comparable with SIDD (11.1 [7.0; 15.5], *P* = 0.40) and MOD (12.8 [8.9; 19.1], *P* = 0.42) (Fig. 2B). Triglycerides were higher in G-allele carrier SIDD patients compared with noncarrier SIDD patients (*P* < 0.05) and not different between carriers and noncarriers in other clusters.

Whole-body insulin sensitivity (M value) was lowest in SIRD (mean  $\pm$  SD 4.5  $\pm$  1.5 mg  $\cdot$  kg<sup>-1</sup>  $\cdot$  min<sup>-1</sup>) compared with SIDD (6.3  $\pm$  2.5, *P* < 0.001), MOD (5.5  $\pm$  2.3, *P* < 0.001), MARD (7.6  $\pm$  2.7, *P* < 0.001), and SAID (8.6  $\pm$  3.0, *P* < 0.001) (Fig. 2C). M value was highest in CON (10.7  $\pm$  3.8 mg  $\cdot$  kg<sup>-1</sup>  $\cdot$  min<sup>-1</sup>) compared with all clusters (all *P* < 0.05) (Supplementary Fig. 1). Basal EGP was lower in SIRD (1.7  $\pm$  0.3 mg  $\cdot$  kg<sup>-1</sup>  $\cdot$  min<sup>-1</sup>) than in SAID and MARD (both 2.0  $\pm$  0.3, both *P* < 0.05) (Supplementary Fig. 1) and comparable with other clusters. Similar results were observed for fasting hepatic insulin resistance index, whereas hepatic insulin sensitivity (% EGP suppression during clamp) did not differ between groups (Fig. 2D). Of note, irrespective of cluster allocation, the rs738409(G) *PNPLA3* variant correlated positively with whole-body insulin sensitivity ( $\beta$  = 0.06, *P* = 0.03) and liver fat content ( $\beta$  = 0.36, *P* = 0.01) across the cohort after adjustments for age, sex, and BMI. Examining the effect of the rs738409(G) *PNPLA3* variant in the classic diabetes types (type 1 and type 2 diabetes) revealed an association of the risk allele with higher adipose tissue insulin resistance and higher liver fat content in people with type 2 diabetes but not in people with type 1 diabetes (Supplementary Fig. 2).

### Hepatic Fat Content and Surrogate Measures of Fibrosis Depending on the rs738409 *PNPLA3* Variant


HCL was higher in SIRD (median 13.6% [1st quartile 5.8; 3rd quartile 19.1]) than in CON (0.9% [0.4; 5.0], *P* < 0.001), SAID (0.4% [0.0; 1.5], *P* < 0.001), MOD (6.4% [2.1; 12.4], *P* = 0.028), and MARD (3.0% [1.0; 7.9], *P* < 0.001) and similar to SIDD (2.4% [0.3; 12.8], *P* = 0.21) (Fig. 3A and Supplementary Fig. 1). Surrogate estimates of hepatic steatosis (FLI) were higher in SIRD (mean  $\pm$  SD 90  $\pm$  11 arbitrary units) compared with CON (46  $\pm$  33, *P* < 0.001),

**Table 1—Patients' characteristics**

	CON	SAID	SIDD	SIRD	MOD	MARD
<i>n</i>	83	254	25	61	240	254
Genotype frequency (CC/CG/GG), <i>n</i>	54/24/5	137/105/12	12/13/0	22/33/6	136/91/13	141/95/18
Female sex, <i>n</i> (%)	26 (31)	117 (46)	5 (20)	17 (28)	108 (45)	71 (28)
Age (years)	47 ± 14	37 ± 12	43 ± 12	56 ± 10	45 ± 10	58 ± 7
BMI (kg/m <sup>2</sup> )	28.2 ± 5.7	25.0 ± 4.3	27.1 ± 3.7	34.5 ± 3.6	34.9 ± 6.3	27.4 ± 3.5
WHR	0.92 ± 0.09	0.88 ± 0.09	0.94 ± 0.06	1.00 ± 0.07	0.97 ± 0.08	0.95 ± 0.07
Fasting blood glucose (mg/dL)	91 ± 15	136 ± 46	187 ± 60	117 ± 21	130 ± 28	123 ± 24
HbA <sub>1c</sub> (%)	5.3 ± 0.3*	6.6 ± 1.2*	8.8 ± 1.3*	6.2 ± 0.7	6.5 ± 0.9	6.3 ± 0.7
HOMA-IR (a.u.)	1.48 ± 0.71*	0.99 ± 0.87*	1.97 ± 0.98	4.48 ± 1.21	2.77 ± 1.01	1.94 ± 0.75*
HOMA-B (a.u.)	122 ± 39	46 ± 31*	39 ± 21*	170 ± 46	98 ± 37*	83 ± 30*
hs-CRP (mg/dL)	0.1 (0.1; 0.2)	0.1 (0.1; 0.2)	0.2 (0.1; 0.4)	0.4 (0.2; 0.6)	0.3 (0.2; 0.7)	0.2 (0.1; 0.3)
Total cholesterol (mg/dL)	205 ± 35	185 ± 38	206 ± 29	197 ± 42	203 ± 44	201 ± 42
LDL cholesterol (mg/dL)	129 ± 33	109 ± 34*	131 ± 29	123 ± 37	130 ± 37	129 ± 36
HDL cholesterol (mg/dL)	61 ± 18*	62 ± 18*	51 ± 12*	42 ± 9	45 ± 12	51 ± 14*
Triglycerides (mg/dL)	93 (62; 148)*	73 (53; 106)*	149 (79; 205)	176 (119; 239)	140 (97; 193)*	117 (83; 161)*
ALT (units/L)	25 ± 11	21 ± 8	26 ± 16	29 ± 13	25 ± 11	24 ± 10
AST (units/L)	28 ± 19*	23 ± 17*	34 ± 18	42 ± 17	37 ± 22*	29 ± 16*
GGT (units/L)	26 ± 18*	22 ± 23*	36 ± 24	49 ± 44	46 ± 62	35 ± 33*

Data are shown as absolute numbers, percentages, mean ± SD, or median (interquartile range), as applicable. a.u., arbitrary units; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT,  $\gamma$ -glutamyl transferase; HOMA-IR, HOMA of insulin resistance; HOMA-B, HOMA of  $\beta$ -cell function; WHR, waist-to-hip ratio. \* $P < 0.05$  vs. SIRD (Dunnett test).

SIDD ( $53 \pm 30$ ,  $P = 0.04$ ), MARD ( $53 \pm 27$ ,  $P < 0.001$ ), and SAID ( $26 \pm 27$ ,  $P < 0.001$ ) and tended to be higher than in MOD ( $81 \pm 25$ ,  $P = 0.07$ ). Among subjects with MOD, carriers of the G allele had slightly lower FLI ( $P < 0.05$ ) (Fig. 3B). Surrogate estimates of liver fibrosis (APRI) were similar between all nonautoimmune diabetes clusters and only showed differences between SIRD and SAID ( $0.20 \pm 0.09$  vs.  $0.28 \pm 0.18$ ,  $P = 0.002$ ). In MARD, carriers of the G allele tended to have higher APRI scores ( $P = 0.06$ ) (Fig. 3C), whereas FIB-4 (Fig. 3D) and NAFLD fibrosis score did not differ between carriers and noncarriers in any cluster. Among people with classical type 2 diabetes, irrespective of cluster allocation, G-allele carriers exhibited higher APRI scores than noncarriers (Supplementary Fig. 2).



**Figure 1**—Genotype distribution of the variant rs738409 in the *PNPLA3* gene stratified by cluster. Bar graphs show percentages of each variant within a cluster. \* $P < 0.05$  vs. CON, MOD, MARD, and SAID.

### Metabolomics


Cluster comparison of the metabolome identified 47 metabolites that differed between SIRD and SAID including the long-chain fatty acids (LCFA) cC18:3w6 and cC20:4w6, sphingomyelins (SM) C18:0 and C18:1, or phosphatidylcholine (PC) aaC38:3 and LCFA-containing PCaaC42:1, C42:4, C42:5, C44:3, C44:4, C44:5, and C44:6 and the lyso-PCs C18:0, C18:1, and C18:2 (Supplementary Fig. 3A). Similarly, PCaaC40:6 was lower in SIDD compared with SIRD (Supplementary Fig. 3B). While only acylcarnitine C3 was higher in SIRD than in MOD (Supplementary Fig. 3C), we identified 12 metabolites, which differed between SIRD and MARD, including SM C18:0, SM C18:1, lyso-PCaC18:1 and C18:2, and PC aaC42:2 and aeC42:3 (Supplementary Fig. 3D). Differences for 16 metabolites remained significant after Bonferroni correction.

Metabolites differed further within all clusters between G-allele carriers and noncarriers ( $P < 0.05$ ). Overall, 13 metabolites including LCFA cC20:4w6 and cC22:4w6 as well as the LCFA-containing PCs, PCaaC36:4, C42:0, C42:1, and PCae C42:4, C42:5, C44:3, C44:4, C44:5, and C44:6 differed between carriers and noncarriers within the SIRD cluster. None of the SNP effects remained significant after Bonferroni correction.

### CONCLUSIONS

This study shows that patients of the recently identified SIRD cluster, featuring higher liver fat content and whole-body insulin resistance, are also more frequently carriers of the G allele in the *PNPLA3* gene. The G allele carriers of this cluster also exhibit higher circulating FFA and higher adipose tissue insulin resistance, while the genetic variant was not associated with HCL or insulin resistance within this group. Of note, across the whole study population, the G allele associated with higher HCL as well as peripheral insulin sensitivity, independent of age, sex, and BMI.

Genetic variation in *PNPLA3* has been shown to associate with both ethnicity-related and individual susceptibility to NAFLD (8). Previous results revealed a synergy between adiposity and genotype indicating that adiposity augments genetic risk of NAFLD at multiple loci that confer susceptibility to hepatic steatosis through diverse mechanisms (26). The current study observed an association of the G allele with increased liver fat content independent of age, sex, and BMI and its higher prevalence in the SIRD cluster, characterized by insulin resistance and increased HCL. This observation extends previous findings associating *PNPLA3* with NAFLD also in individuals with diabetes by




**Figure 2**—Metabolic characteristics of the study population stratified by cluster and *PNPLA3* genotype. Data are presented as median and interquartile range. Depicted are differences in circulating FFA (A), adipose tissue insulin sensitivity (B), whole-body insulin sensitivity (C), and hepatic insulin sensitivity (D). \* $P < 0.05$ ; # $P < 0.05$  after adjustments for age and sex. Adipo-IR, adipose tissue insulin resistance index.

describing particularly higher risk of NAFLD in patients with severe insulin resistance. Thus, these findings support the notion that inhibition of the variant *PNPLA3* activity may represent a promising target for novel treatment concepts of NAFLD (15).

Furthermore, previous studies suggested that *PNPLA3* is involved not only in hepatic steatosis but also fibrosis. This may occur, as the *PNPLA3* mutation can inhibit retinyl-esterase activity in hepatic stellate cells, where it is involved in retinol

metabolism and plays an important role in lipid droplet remodeling (27). Consequently, loss of function in *PNPLA3* may associate with reduced release of retinol from lipid droplets and subsequent propensity to liver fibrosis (28). Analysis of the



**Figure 3**—Liver parameters of the study population stratified by diabetes cluster and *PNPLA3* genotype. Data are presented as median and interquartile range. Depicted are differences in liver fat content (A), FLI (B), and liver fibrosis indices APRI (C) and FIB-4 (D). \* $P < 0.05$ ; # $P < 0.05$  after adjustments for age and sex.

clusters separately revealed no association of any liver fibrosis surrogate with the *PNPLA3* mutation, whereas higher APRI scores associated with the G allele among the entire type 2 diabetes cohort. Of note, our study population exclusively comprised patients with recently diagnosed diabetes. While this allowed us to monitor early metabolic abnormalities without interference from long-term hyperglycemia and dyslipidemia, these recently diagnosed patients are likely at low risk of liver fibrosis.

The current study detected an association of the *PNPLA3* genotype with increased peripheral insulin sensitivity across the whole cohort but not within the individual clusters—except for lower insulin sensitivity along with higher serum triglycerides in the G-allele carriers in the SIDD group, possibly due to insulin deficiency. The relationship between the risk allele and insulin resistance remains controversial. The present data confirm previous reports on a disassociation between insulin resistance and fatty liver in G-allele carriers (17,29). The underlying mechanisms may involve lower availability of (monoun)saturated fatty acids—despite higher fat content—for activation of the hepatic diacylglycerol/protein kinase C $\epsilon$  pathway, which would prevent lipid-induced whole-body insulin resistance (15). Indeed, *PNPLA3*-associated NAFLD has previously been associated with increases in hepatic polyunsaturated triglycerides (8,29). *PNPLA3* may sequester  $\alpha/\beta$ -hydrolase domain-containing 5 (ABHD5) (also known as CGI-58), and prevents it from activating *PNPLA2*, a major intracellular adipose and hepatic triglyceride lipase, triggering triglyceride accumulation in adipose tissue and liver (30). Along these lines, previous studies suggest that the higher liver fat content in G-allele carriers is caused by reduced mobilization of triglycerides from lipid droplets, rather than by increased triglyceride synthesis from either endogenously synthesized or circulating fatty acids (31). Our study detected differences in FFA and adipose tissue insulin resistance in noncarriers compared with G-allele carriers of the SIRD cluster. SIRD patients in turn showed highest liver fat content, independently of *PNPLA3* genotype. Nevertheless, adipose tissue insulin resistance and lipolysis might mutually accelerate NAFLD and diabetes progression.

The heterogeneity in insulin sensitivity among diabetes cohorts can be at least partly attributed to differences in abdominal fat volume (32). Particularly, abdominal

visceral obesity is associated with adipose tissue insulin resistance and impaired glucometabolic control (21). The subgroup analysis of the current study did not detect any difference in adipose tissue volumes between G-allele carriers and noncarriers, further suggesting that *PNPLA3* could affect adipose tissue function rather than mass. Lipotoxic FFA, mainly saturated fatty acids, diacylglycerols, and ceramides, have been identified as possible causal factors underlying obesity- and diabetes-related insulin resistance and NAFLD (1,3,7). The current study found that SIRD patients have certain higher PC and SM species, which have been proposed to link NAFLD and diabetes onset (33). Of note, lyso-PCa18:2 differed between SIRD and SAID as well as MARD, two clusters that had lower HCL compared with SIRD. Lyso-PCa18:2 associates with diabetes progression (33) but was not affected by the carrier status in this study. On the molecular level, the PCaa lipids are major components of human lipoproteins and involved in the release of triglyceride-enriched VLDLs (34). In contrast, PCae lipids inhibit lipid oxidation and have cell-protective properties (35), while SM may interfere with reactive oxygen species and decrease insulin secretion and signaling (36). In SIRD, the presence of the SNP affected arachidonic acid cC20:4w6. Along these lines, cC20:4-containing PC species have been shown to correlate negatively with insulin sensitivity (37). Taken together, results show that the SIRD cluster presents with alterations in the circulating metabolome consistent with patterns linked to insulin resistance, which specifically differ compared with other clusters.

Furthermore, there is evidence that adipose tissue dysfunction and insulin resistance may prevail during the early stage of type 2 diabetes without relevant hepatic insulin resistance (1). Adipose tissue insulin resistance would favor hepatic triglyceride accumulation and NAFLD in the absence of inadequate adaptation of mitochondrial function (6) before hepatic insulin resistance would occur at later disease stages. One might speculate that the *PNPLA3* variant could directly affect adipocyte function and thereby induce adipose tissue insulin resistance. Indeed, mRNA expression of *PNPLA3* was originally detected in murine adipocytes and can also be upregulated during human adipocyte differentiation despite overall lower expression compared with in liver (38). In this context, changes of the saturation of FFA and triglycerides as observed in liver (39) might differently affect

the FFA composition of circulating FFA and in turn whole-body and hepatic insulin resistance.

Previous findings indicate that NAFLD is associated with an increased risk of cardiovascular events (1,2). In line, cluster analysis of a Swedish population revealed increased cardiovascular risk specifically in patients with SIRD (4). This process may occur through the systemic release of proatherogenic mediators from the diseased liver or through the contribution of NAFLD to insulin resistance and dyslipidemia, which are important risk factors for cardiovascular disease (1,2). This is particularly relevant for patients of the SIRD cluster who present with high triglycerides, increased FFA, and high whole-body and tissue-specific insulin resistance. Consequently, it is paramount for clinicians to consider intensified cardiovascular risk factor management in patients with SIRD and NAFLD.

The current study benefits from the comprehensive phenotyping applying gold standard methods to assess insulin sensitivity and HCL and from the comparison with a metabolically healthy CON group. In addition, the recruitment of patients with recent-onset diabetes allows for metabolic studies avoiding interference from chronic metabolic dysregulation or long-term treatment effects. On the other hand, while using state-of-the-art noninvasive measures to quantify liver fat, we had to rely on liver fibrosis indices, as liver biopsies were not available for the current study. Of note, MRS techniques have proven to have lower reliability due to limited spatial coverage and higher variability in obese persons due to specific hardware requirements. MRI-based assessment of proton density fat fraction combined with MR elastography will likely overcome current limitations and provide additional information on hepatic fibrosis in future studies (40). The one-step clamp test is optimized for the assessment of whole-body insulin sensitivity but has lower sensitivity for detecting smaller differences in hepatic and adipose tissue insulin sensitivity. Furthermore, the comprehensive phenotyping approach and the exclusion criteria of the GDS (19) may lead to a selected population, which will require further studies in population-based cohorts. Finally, the low absolute number of SIRD patients is another limitation but also reflects the lower prevalence among the other



subtypes, which is in good agreement with that of other larger cohorts (4).

In conclusion, patients of the SIRD cluster are more frequently carriers of the G allele in the *PNPLA3* gene, which associates with increased circulating FFA levels and adipose tissue insulin resistance. They also present with the highest hepatocellular lipid content and whole-body insulin resistance, which did not associate with the carrier status. These results are suggestive of a lipotoxic milieu in carriers of the G allele, which may accelerate whole-body and tissue-specific insulin resistance and NAFLD. Collectively, these observations warrant the screening of persons at highest risk of NAFLD and targeting reduction of adipose tissue insulin resistance for the prevention and treatment of NAFLD in people with diabetes.

**Funding.** The GDS was initiated and is financed by the German Diabetes Center (which is funded by the German Federal Ministry of Health and the Ministry of Culture and Science of the state of North Rhine-Westphalia) and the German Federal Ministry of Education and Research (to the German Center for Diabetes Research). Parts of the study are also supported by grants from the German Research Foundation (Research Network SFB 1116), the German Diabetes Association, and the Schmutzler Stiftung. The funding sources had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

**Duality of Interest.** M.R. reports personal fees from Allergan, AstraZeneca, Boehringer Ingelheim Pharma, Bristol-Myers Squibb, Fishawack Health, Gilead Sciences, Intercept Pharma, Novo Nordisk, Nutricia-Danone, ProSclero, Sanofi U.S., TARGET PharmaSolutions, and Terra Firma. No other potential conflicts of interest relevant to this article were reported.

**Author Contribution.** O.P.Z. wrote the manuscript and researched data. K.S. performed the statistical analyses. B.K. and J.K. performed the genetic analyses. Y.Ku. and J.-H.H. performed and analyzed the metabolic imaging data. Y.Ka., M.W., K.B., D.F.M., V.B., H.A.-H., J.S., and M.R. researched data, contributed to the discussion, and reviewed and edited the manuscript. All authors critically reviewed the manuscript. All authors read and approved the final manuscript. M.R. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Prior Presentation.** Parts of this study were presented in abstract form at the 80th Scientific Sessions of the American Diabetes Association, 12–16 June 2020.

## References

1. Roden M, Shulman GI. The integrative biology of type 2 diabetes. *Nature* 2019;576:51–60
2. Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. *Nat Rev Endocrinol* 2018;14:99–114

3. Gancheva S, Jelenik T, Álvarez-Hernández E, Roden M. Interorgan metabolic crosstalk in human insulin resistance. *Physiol Rev* 2018;98:1371–1415
4. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol* 2018;6:361–369
5. Zaharia OP, Strassburger K, Strom A, et al.; German Diabetes Study Group. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. *Lancet Diabetes Endocrinol* 2019;7:684–694
6. Koliaki C, Szendroedi J, Kaul K, et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. *Cell Metab* 2015;21:739–746
7. Apostolopoulou M, Gordillo R, Koliaki C, et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in non-alcoholic steatohepatitis. *Diabetes Care* 2018;41:1235–1243
8. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in *PNPLA3* confers susceptibility to non-alcoholic fatty liver disease. *Nat Genet* 2008;40:1461–1465
9. Trépo E, Romeo S, Zucman-Rossi J, Nahon P. *PNPLA3* gene in liver diseases. *J Hepatol* 2016;65:399–412
10. Koo BK, Joo SK, Kim D, et al. Additive effects of *PNPLA3* and *TM6SF2* on the histological severity of non-alcoholic fatty liver disease. *J Gastroenterol Hepatol* 2018;33:1277–1285
11. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. *J Hepatol* 2018;68:268–279
12. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016;64:1388–1402
13. Liu YM, Moldes M, Bastard J-P, et al. Adiponutrin: a new gene regulated by energy balance in human adipose tissue. *J Clin Endocrinol Metab* 2004;89:2684–2689
14. Qiao A, Liang J, Ke Y, et al. Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis. *Hepatology* 2011;54:509–521
15. Kumashiro N, Yoshimura T, Cantley JL, et al. Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats. *Hepatology* 2013;57:1763–1772
16. Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a *PNPLA3* protein isoform (I148M) associated with nonalcoholic fatty liver disease. *J Biol Chem* 2011;286:37085–37093
17. Franko A, Merkel D, Kovarova M, et al. Dissociation of fatty liver and insulin resistance in I148M *PNPLA3* carriers: differences in Diacylglycerol (DAG) FA18:1 lipid species as a possible explanation. *Nutrients* 2018;10:1314
18. Dongiovanni P, Stender S, Pietrelli A, et al. Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver. *J Intern Med* 2018;283:356–370
19. Szendroedi J, Saxena A, Weber KS, et al.; GDS Group. Cohort profile: the German Diabetes Study (GDS). *Cardiovasc Diabetol* 2016;15:59

20. American Diabetes Association. 2. Classification and diagnosis of diabetes: *Standards of Medical Care in Diabetes—2020*. *Diabetes Care* 2020;43(Suppl. 1):S14–S31
21. Gastaldello A, Gaggini M, DeFronzo RA. Role of adipose tissue insulin resistance in the natural history of type 2 diabetes: results from the San Antonio Metabolism Study. *Diabetes* 2017;66:815–822
22. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. *Hepatology* 2017;66:1486–1501
23. Laufs A, Livingstone R, Nowotny B, et al. Quantitative liver  $^{31}\text{P}$  magnetic resonance spectroscopy at 3T on a clinical scanner. *Magn Reson Med* 2014;71:1670–1675
24. Machann J, Thamer C, Stefan N, et al. Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes. *Radiology* 2010;257:353–363
25. Knebel B, Strassburger K, Szendroedi J, et al.; German Diabetes Study Group. Specific metabolic profiles and their relationship to insulin resistance in recent-onset type 1 and type 2 diabetes. *J Clin Endocrinol Metab* 2016;101:2130–2140
26. Stender S, Kozlitina J, Nordestgaard BG, Tybjaerg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. *Nat Genet* 2017;49:842–847
27. Pirazzi C, Valenti L, Motta BM, et al. *PNPLA3* has retinyl-palmitate lipase activity in human hepatic stellate cells. *Hum Mol Genet* 2014;23:4077–4085
28. Pingitore P, Dongiovanni P, Motta BM, et al. *PNPLA3* overexpression results in reduction of proteins predisposing to fibrosis. *Hum Mol Genet* 2016;25:5212–5222
29. Luukkainen PK, Zhou Y, Sädevirta S, et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. *J Hepatol* 2016;64:1167–1175
30. Yang A, Mottillo EP, Mladenovic-Lucas L, Zhou L, Granneman JG. Dynamic interactions of ABHD5 with *PNPLA3* regulate triacylglycerol metabolism in brown adipocytes. *Nat Metab* 2019;1:560–569
31. BasuRay S, Smagris E, Cohen JC, Hobbs HH. The *PNPLA3* variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. *Hepatology* 2017;66:1111–1124
32. Preis SR, Massaro JM, Robins SJ, et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. *Obesity (Silver Spring)* 2010;18:2191–2198
33. Floegel A, Stefan N, Yu Z, et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. *Diabetes* 2013;62:639–648
34. Quehenberger O, Dennis EA. The human plasma lipidome. *N Engl J Med* 2011;365:1812–1823
35. Wallner S, Schmitz G. Plasmalogens the neglected regulatory and scavenging lipid species. *Chem Phys Lipids* 2011;164:573–589
36. Yano M, Watanabe K, Yamamoto T, et al. Mitochondrial dysfunction and increased reactive oxygen species impair insulin secretion in sphingomyelin synthase 1-null mice. *J Biol Chem* 2011;286:3992–4002

37. Koeberle A, Shindou H, Koeberle SC, Laufer SA, Shimizu T, Werz O. Arachidonoyl-phosphatidylcholine oscillates during the cell cycle and counteracts proliferation by suppressing Akt membrane binding. *Proc Natl Acad Sci U S A* 2013;110:2546–2551
38. Wilson PA, Gardner SD, Lambie NM, Commans SA, Crowther DJ. Characterization of the human patatin-like phospholipase family. *J Lipid Res* 2006;47:1940–1949
39. Luukkonen PK, Nick A, Hölttä-Vuori M, et al. Human *PNPLA3*-I148M variant increases hepatic retention of polyunsaturated fatty acids. *JCI Insight* 2019;4:e127902
40. Loomba R. Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions. *J Hepatol* 2018;68:296–304